文献速递系统性红斑狼疮

贝利尤单抗联合标准治疗在系统性红斑狼疮中的感染性并发症:系统评价与荟萃分析

Infectious complications of Belimumab with standard care in systemic lupus erythematosus: a systematic review and meta-analysis.
PubMed 文献 · Semin Arthritis Rheum · 2025-05-14

本系统评价与荟萃分析纳入8项研究共8545例系统性红斑狼疮(SLE)患者,评估贝利尤单抗联合标准治疗与感染性并发症风险的关系。结果显示,除支气管炎外,感染、严重感染、鼻咽炎、上呼吸道感染、尿路感染、带状疱疹和流感的风险均未显著增加;SLEDAI和BILAG亚组分析未显示对感染性并发症的显著影响。

要点

  • 贝利尤单抗(静脉≤10 mg/kg)联合标准治疗未显著增加SLE患者感染、严重感染等风险,但支气管炎风险呈现升高趋势。
  • 基线疾病活动度(SLEDAI)和器官损伤(BILAG 1A/2B比例)亚组分析未显示对感染性并发症的显著影响。
  • 纳入的8项研究中4项存在高失访偏倚,结论需谨慎解读。

核心结论

  • 荟萃分析结果表明,静脉贝利尤单抗(≤10 mg/kg)联合标准治疗未显著增加轻至中度疾病活动度SLE患者的感染性并发症风险,但支气管炎除外。
  • 基线疾病活动度和器官损伤未影响感染性并发症风险。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Web of Science、EMBASE和Cochrane数据库,纳入8项研究共8545例SLE患者,采用Cochrane ROB 2工具评估研究质量,随机效应模型分析,Egger检验评估发表偏倚,并按SLEDAI和BILAG进行亚组分析,方案注册于PROSPERO(CRD42023421255)。

主要发现

  • 感染风险:RR=1.02(95%CI 0.97-1.08),I²=7.7%。
  • 严重感染风险:RR=0.94(95%CI 0.77-1.15),I²=0%。
  • 鼻咽炎风险:RR=1.02(95%CI 0.79-1.33),I²=36%。
  • 上呼吸道感染风险:RR=0.97(95%CI 0.83-1.14),I²=20.6%。
  • 尿路感染风险:RR=1.09(95%CI 0.91-1.32),I²=0%。

关键数值与推荐

  • 带状疱疹风险:RR=0.75(95%CI 0.54-1.05),I²=0%。
  • 流感风险:RR=0.98(95%CI 0.69-1.39),I²=0%。
  • 支气管炎风险:RR=1.51(95%CI 0.98-2.33),I²=23.7%。
  • SLEDAI和BILAG 1A/2B比例亚组分析未显示对感染性并发症的显著影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 纳入的8项研究中有4项存在高失访偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to evaluate the risk of infectious complications of Belimumab with standard care in systemic lupus erythematosus (SLE). METHODS: We searched PubMed, Web of Science, EMBASE, and Cochrane databases for studies on SLE and Belimumab and evaluated the study quality using the Cochrane Collaboration tool (ROB 2). A random-effect model was employed to analyze the results. To evaluate publication bias, Egger's tests were used. We also performed subgroup analysis based on the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group(BILAG). The study protocol has been registered in PROSPERO (CRD42023421255). RESULTS: Eight studies involving 8545 patients were included, of which four studies had a high attrition bias. The present study suggested that the risks of infectious complications including infection (RR=1.02, 95 %CI=(0.97,1.08), I2=7.7 %) or serious infections (RR=0.94, 95 %CI=(0.77,1.15), I2=0 %), nasopharyngitis(RR=1.02, 95 %CI=(0.79,1.33), I2=36 %), upper respiratory tract infection(RR=0.97, 95 %CI=(0.83,1.14), I2=20.6 %), urinary tract infection(RR=1.09, 95 %CI=(0.91,1.32), I2=0 %), herpes zoster (RR=0.75, 95 %CI=(0.54,1.05), I2=0 %)and influenza(RR=0.98, 95 %CI=(0.69,1.39), I2=0 %) were not significantly increased in patients who received Belimumab with standard care, except for bronchitis (RR=1.51, 95 %CI=(0.98,2.33), I2=23.7 %). Additionally, the subgroup analysis of SLEDAI and the proportion of patients with BILAG 1A/2B did not show any significant impact on infectious complications. CONCLUSION: Meta-analysis results demonstrated that intravenous (IV) Belimumab(≤10 mg/kg), along with standard care, did not significantly increase the risk of infectious complications in SLE patients having mild-to-moderate disease activity, except for bronchitis. Baseline disease activity and organ damage did not impact the risk of infectious complications.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Chi G, Xia S, et al. Infectious complications of Belimumab with standard care in systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum. 2025. PMID: 40398101. doi:10.1016/j.semarthrit.2025.152754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。